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S U M M A R Y
Visceral leishmaniasis is an enzootic parasitosis present across the Mediterranean Basin. Some consider
it an opportunistic parasite. We report the case of a girl treated with anti-tumour necrosis factor alpha
(anti-TNFa) for juvenile idiopathic arthritis who had previously presented with visceral leishmaniasis.
Two and a half years later, she presented a tumour-like mass in the nasal mucous membrane caused by
Leishmania parasites. Leishmania infantum is classically responsible for visceral leishmaniasis, but pure
mucocutaneous leishmaniasis has also been described. To our knowledge, this is the ﬁrst observation of a
recurrence of visceral leishmaniasis in the mucocutaneous form. The occurrence of atypical forms and
presentations in those on anti-TNF therapy should be considered.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Visceral leishmaniasis (VL) is an endemic vector-borne and
zoonotic–anthroponotic parasitosis found across the Mediterra-
nean Basin. The causal agent is an obligate intracytomacrophagic
protozoan, Leishmania infantum. VL is a life-threatening infection.
Signs and symptoms include hectic fever, hepatosplenomegaly,
and cytopenia. Sporadic cases with a cutaneous or mucous
localization have been described. We report the ﬁrst case of a
child presenting both forms of the disease.
2. Case report
In 2001, a 4-year-old girl presented with mono-articular
juvenile idiopathic arthritis (JIA) and bilateral uveitis. She was
living in the Languedoc Roussillon area in the south of France, an
area endemic for L. infantum, and had never travelled outside this
area. In April 2002 she commenced treatment with prednisolone at* Corresponding author.
E-mail address: e-jeziorski@chu-montpellier.fr (E. Jeziorski).
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license (http://creativecommons.org/licenses/by-nc-sa/4.0/).a starting dose of 2 mg/kg, but relapses required the addition of
anti-tumour necrosis factor alpha (anti-TNFa) therapy in February
2003. Etanercept was the anti-TNFa agent used until January
2004; following this inﬂiximab was given at doses of 5 to 20 mg/kg
every 6 weeks, leading to disease remission. The injections were
then given every 8 weeks.
In January 2005, after seven inﬂiximab treatments, the patient
developed a fever lasting 15 days and was then admitted to
hospital. Physical examination ﬁndings were asthenia, paleness,
and hepatosplenomegaly. Laboratory test ﬁndings were the
following: C-reactive protein 23 mg/l and bicytopenia (haemoglo-
bin 11.4 g/dl, platelet count 76  109/l, white blood cell count
4.09  109/l). VL was conﬁrmed by examination of bone marrow
aspirate: direct examination of May–Gru¨nwald–Giemsa-stained
smears revealed Leishmania parasites. Serological tests were also
positive: indirect ﬂuorescent antibody test (IFAT) 1/5120 (cut-off
1/80), and ELISA 2.33 (cut-off 0.32). PCRs of whole blood and bone
marrow aspirate were positive for L. infantum.
The patient was treated with intravenous liposomal amphoter-
icin B 24 mg/kg in six doses. The outcome was favourable and the
anti-TNFa treatment was maintained. After this curative treat-
ment, the patient received prophylactic amphotericin B treatmentciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. Granuloma with Leishmania inside macrophages (haematoxylin–eosin
stain, 60).
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stopped 4 months later due to non-tolerance (vomiting).
In July 2007, 26 months after amphotericin B therapy had
ceased, she suffered recurrent epistaxis. An intra-nasal tumour was
identiﬁed in November 2007. Clinical examination showed the
tumour to be located in the median septum near the nasal opening.
The patient presented no hepatosplenomegaly or fever. Magnetic
resonance imaging (MRI) showed a paramedian tissue mass of
14  6.5 mm without osteo-cartilaginous invasion.
An excision biopsy was performed; pathological examination
revealed a granuloma with macrophages containing Leishmania
parasites (Figure 1). Positive PCR results conﬁrmed the diagnosis of
L. infantum in the mucosal lesion. Further investigations
for extension, including bone marrow examination, speciﬁc PCR
for L. infantum in blood, bone marrow aspiration, and gastro-
oesophageal ﬁbroscopy, were negative.
No other localizations or relapses occurred during the following
5-year period, hence no further medical treatment has been given
for Leishmania. In light of the severity of the uveitis related to the
JIA, the patient has continued to receive anti-TNFa therapy,
steroids, and methotrexate since March 2008.
3. Discussion
L. infantum is classically responsible for VL or cutaneous
leishmaniasis, but rare mucosal forms or lesions have been
described. Nasal leishmaniasis is a rare mucosal form. A Spanish
study has described ﬁve cases in a group of 31 patients withmucocutaneous leishmaniasis; in that study, the mucosal presen-
tation was in the form of nodular swelling or pseudo-tumoural
masses in 25 cases.1
Several clinical cases of VL occurring in patients on anti-TNFa
therapy have been reported in the literature. For example, a 45-
year-old Greek man with psoriatic arthritis, receiving treatment
with inﬂiximab, who was treated with amphotericin B with a good
outcome.2
The leishmaniasis immune response has been studied exten-
sively, but is not yet well understood. Furthermore, much progress
has been made in recent years concerning the role of TNFa in
experimental and clinical studies. Many experimental studies have
shown the positive impact of TNF in the anti-Leishmania response:
mortality rates are high without TNF production.3 However other
studies have suggested that the toxic action of high levels of TNF
cause dysregulation of chemokines and of the immune response to
leishmaniasis.3 In human disease, elevated levels of TNFa in the
blood have been shown to be associated with the visceral forms in
cytokine studies. Moreover, human genetic studies have shown
that certain TNF polymorphisms are more frequent in VL than in
benign forms; these polymorphisms increase baseline TNF levels.4
Cutaneous leishmaniasis has a different pathway to VL.
However, it has been shown that in cutaneous leishmaniasis,
TNFa levels persist in tissues even after healing,5 indicating that it
has a role in preventing relapse by an immune-regulatory
mechanism; this explains the occurrence of relapse under anti-
TNFa therapy.
In conclusion, our case is interesting because it is the ﬁrst to
show recurrence of VL in the mucocutaneous form; it may also
reﬂect the complex role of TNFa. The mucosal lesion was probably
a relapse, but this is not certain because the strains were not
characterized. The fact that this uncommon presentation occurred
under anti-TNFa therapy suggests its role in this clinical case,
which is supported by experimental data.
TNF has a variety of roles in experimental VL. Some beneﬁt host
resistance, while others mediate host pathology. More studies are
required to clarify its role in human disease as it could have
application in terms of diagnosis or therapy.
Conﬂict of interest: No conﬂict of interest; no funding.
References
1. Aliaga L, Cobo F, Mediavilla JD, Bravo J, Osuna A, Amador JM, et al. Localized
mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and
microbiologic ﬁndings in 31 patients. Medicine (Baltimore) 2003;82:147–58.
2. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic
arthritis treated with inﬂiximab: reactivation of a latent infection? Clin Rheu-
matol 2008;27:541–2.
3. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, et al. The immunopa-
thology of experimental visceral leishmaniasis. Immunol Rev 2004;201:239–53.
4. Karplus TM, Jeronimo SM, Chang H, Helms BK, Burns TL, Murray JC, et al.
Association between the tumor necrosis factor locus and the clinical outcome
of Leishmania chagasi infection. Infect Immun 2002;70:6919–25.
5. Blackwell JM. Tumour necrosis factor alpha and mucocutaneous leishmaniasis.
Parasitol Today 1999;15:73–5.
